TCGX to Merge With TriGemX Bio in $160M-PIPE SPAC Deal at ~$599M Equity Value
TCGX sits 20% above its 52-week low of $10.3.
Summary
TCGX signed a definitive merger with TriGemX Bio, pairing a $361M pre-money valuation with a $160M PIPE at $10.00 per share for roughly $599M pro forma equity value. Proceeds fund Phase 3 migraine trials for elismetrep, with first pivotal data expected mid-2027.
Key Events · M&A and Partnerships · TCGX
-
Definitive Merger With TriGemX Bio
TCGX will domesticate to Delaware and merge with TriGemX Bio (formerly Kallyope), with TriGemX holders rolling 100% of equity at a $361M pre-money value and a $10.00 reference share price.
-
$160M PIPE at $10.00 Per Share
16,000,000 shares sold to TCGX, Viking Global, ADAR1, BVF Partners, Samsara BioCapital, Vianti Capital and others; combined with ~$86.7M in trust, expected gross proceeds are ~$246M before fees.
-
Cash Condition and Sponsor Forfeiture
Closing requires at least $150M of available cash after redemptions; the sponsor forfeits up to 539,062 founder shares if available cash falls below $161M, scaling down to zero forfeiture at $161M or above.
-
Proceeds Fund Phase 3 Through NDA
Capital covers the ongoing elismetrep Phase 3 acute-migraine trials, a prevention trial, and commercial readiness; first pivotal topline is expected mid-2027, second early 2028, with an NDA targeted mid-2028.
Analysis · TCGX · Life Sciences
TCGX, a SPAC that raised roughly $91.5M in its August 2026 IPO, is combining with TriGemX Bio (formerly Kallyope), the developer of elismetrep, an oral TRPM8 blocker in Phase 3 for acute migraine. The deal carries a $361M pre-money equity value for TriGemX and a concurrent $160M PIPE at $10.00 per share from a blue-chip healthcare syndicate, implying roughly $599M pro forma equity value and about $403M enterprise value assuming no redemptions. That capital is earmarked to finish the Phase 3 program and prepare a US launch, with first pivotal data expected mid-2027 and an NDA targeted for mid-2028. The main risk is redemption: the deal only closes if available cash, including the trust and PIPE, reaches $150M, and the sponsor forfeits up to 539,062 founder shares if it falls below $161M. For TCGX holders this converts a cash trust into a clinical-stage biotech equity story with binary Phase 3 readouts ahead.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCGX was trading at $12.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $139M. The 52-week trading range was $10.30 to $18.91. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.